ClinFomatrix, a Leading Contract Research Organization, in Edison, New Jersey, USA; Specialized in Triple-Negative Breast Cancer (TNBC) drug development and help pharma companies to bring the drug in the market. The metastatic triple-negative breast cancer is estrogen-receptor–negative and progesterone-receptor–negative and has no overexpression of human epidermal growth factor receptor type 2 (HER2); is a highly aggressive subtype of breast cancers with higher rates of visceral and central nervous system metastases and poor survival. Patients with triple-negative breast cancer treated with chemotherapy have higher rates of pathological complete response. However, patients in whom metastatic disease develops have a very poor prognosis, therefore it’s an Unmet Medical Needs in medicine to treat patients with Triple-Negative Breast Cancer. Contact Dr. Srivastava for further clinical trial related services globally and study design consultancy. [email protected]
